NASDAQ: EWTXEdgewise Therapeutics Inc Stock
$15.08-0.15 (-0.98%)
Updated Apr 22, 2024
EWTX Price
$15.08
Fair Value Price
$1.27
Market Cap
$1.40B
52 Week Low
$5.12
52 Week High
$20.69
P/E
-9.61x
P/B
4.4x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$100.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$92M
Beta
1.37
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
EWTX Overview
Edgewise Therapeutics, Inc., a biopharmaceutical company, is developing small molecule therapies for musculoskeletal diseases. The company's product candidates target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics was incorporated in 2017 and is headquartered in Boulder, CO.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EWTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EWTX ($15.08) is overvalued by 1,091.02% relative to our estimate of its Fair Value price of $1.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EWTX ($15.08) is not significantly undervalued (1,091.02%) relative to our estimate of its Fair Value price of $1.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EWTX due diligence checks available for Premium users.
Be the first to know about important EWTX news, forecast changes, insider trades & much more!
EWTX News
Valuation
EWTX fair value
Fair Value of EWTX stock based on Discounted Cash Flow (DCF)
Price
$15.08
Fair Value
$1.27
Overvalued by
1,091.02%
EWTX ($15.08) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EWTX ($15.08) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EWTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EWTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.61x
Industry
16.21x
Market
41x
EWTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.4x
Industry
5.82x
EWTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EWTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$30.1M
Profit Margin
0%
EWTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$340.0M
Liabilities
$21.2M
Debt to equity
0.07
EWTX's short-term assets ($327.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EWTX's short-term assets ($327.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EWTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.8M
Investing
$27.0M
Financing
$53.0M
EWTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EWTX vs Biotech Stocks
Edgewise Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.